|
This issue of Advances in Pulmonary Hypertension renews
our commitment to the pulmonary hypertension community to provide valuable,
timely, peer-reviewed scientific information relevant to clinical practice.
Beginning with its first issue more than 3 years ago, the journal has
embodied a team effort. Reflecting the fact that pulmonary hypertension
is a complex disease, our editorial focus has been derived from experts
whose areas of concentration reflect the diverse nature of this disorder
and its complications.
As I assume the role of Editor-in-Chief, I pursue the same strategy
because it has served us well. We will continue to build on a team
effort of national and international experts whose goal is to find
a cure for pulmonary hypertension. While the cure remains elusive,
we are finding significant ways to improve the quality of life of patients
with the disease; the journal serves as a chronicle of that story as
it focuses on important developments in translational research and
relates them to clinical considerations and decisions.
We are challenged by and appreciative of the leadership provided during
the first 3 years of publication. We gratefully acknowledge the hard
work and guidance provided by Victor F. Tapson, MD, Editor-in-Chief
during this time. His contribution to the launch of the journal has
left us with a solid foundation on which to build. His high editorial
standards give us a legacy to live up to and the enthusiastic response
to the journal from 30,000 readers makes us proud of Vic’s contribution.
We are also grateful for the guidance provided by the Editorial Advisory
Board of Richard N. Channick, MD, Sean Gaine, MD, PhD, Ronald J. Oudiz,
MD, and Ivan M. Robbins, MD. The help from these leading academicians
in identifying appropriate topics, participating in roundtable discussions
and ensuring the overall quality of content inspires us to continue
their excellent work.
With this issue, you will see more evidence of our team approach to
pulmonary hypertension. Drs Channick and Oudiz will remain as Associate
Editors, and we have added Ramona Doyle, MD, Karen Fagan, MD, and Oliver
Sitbon, MD. Our Editorial Advisory Board has been expanded because
more physicians have expressed a special interest in the journal and
we look forward to working with them throughout the year as they participate
in the editorial process. These physicians include: Gregory Ahearn,
MD, Jacques Benisty, MD, Raymond Benza, MD, Erika Berman- Rosenzweig,
MD, Todd Bull, MD, Murali Chakinala, MD, Jeffrey Edelman, MD, Jim Maloney,
MD, Robert Schiltz, DO, and Roxana Sulica, MD.
The result will be a journal that reflects the broadest possible
spectrum of expert medical opinion in pulmonary hypertension. The journal
also benefits from the expertise of the Scientific Leadership Council
of the Pulmonary Hypertension Association (PHA). As the official journal
of PHA, Advances in Pulmonary Hypertension will continue to be in the
forefront of patient advocacy and awareness concerning the availability
of new research grants as well, serving as the most comprehensive resource
for such information. The enthusiastic response from our readers is
another key factor in renewing our commitment to the pulmonary hypertension
community. We look forward to hearing from you regarding the usefulness
of the content and welcome your suggestions and comments as we work
toward providing you with a journal you look forward to reading, saving,
and sharing with colleagues.
Vallerie V. McLaughlin, MD
Editor-in-Chief |
